Amgen Inc. may ultimately have to pay as much as $10.7 billion in taxes, interest and penalties to the IRS—nearly as much as ...
With the recent spike in implied volatility, an iron condor on Amgen can use short strikes with a wide profit range.
Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop ...
Make America Healthy Again starts TOMORROW,” joked Donald Trump Jr. in a post on X sharing the picture. While it is hard to ...
Lilly's drug is the only oral treatment in a field of several injectable therapies being tested to treat high Lp(a), a risk factor for heart disease that affects one in five individuals globally ...
Janux Therapeutics' innovative cancer treatment shows promise in reducing side effects and improving patient outcomes, but ...
On Friday, Amgen Inc (AMGN) stock saw a decline, ending the day at $283.61 which represents a decrease of $-12.32 or -4.16% from the prior close of $295.93. The stock opened at $291.5 and touched a ...
In the ongoing case of Carefirst of Maryland Inc. v. Johnson & Johnson, the plaintiffs successfully overcame a motion to ...
Analyzing Amgen's stock drop, management's response, and potential for growth in GLP-1 candidate MariTide in a volatile ...
For patients at high risk of stroke who underwent catheter-based atrial fibrillation ablation, left atrial appendage closure ...
Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...
On November 13, 2024, Amgen filed a BPCIA complaint in the District Court for the Eastern District of North Carolina against Accord Biopharma, Inc.; Accord Healthcare, Inc.; and Intas Pharmaceuticals, ...